Quick Answer
Pyxis Oncology, Inc. reported Stockholders Equity of $53.41 million for the year ending 2025.
- Pyxis Oncology, Inc. showed a decrease of -55.8% in Stockholders Equity from 2024 to 2025.
- This data is from Pyxis Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$4.82 million | Q2 2020: -$7.91 million | Q3 2020: -$11.09 million | Q1 2021: -$50.02 million | Q2 2021: -$57.59 million | Q3 2021: -$71.44 million | Q1 2022: $233.51 million | Q2 2022: $211.97 million | Q3 2022: $188.75 million | Q1 2023: $152.16 million | Q2 2023: $145.28 million | Q3 2023: $137.95 million | Q1 2024: $184.16 million | Q2 2024: $169.79 million | Q3 2024: $153.68 million | Q1 2025: $103.10 million | Q2 2025: $87.64 million | Q3 2025: $68.78 million.
- Over the full 7 years of available data (2019 to 2025), Pyxis Oncology, Inc.'s Stockholders Equity has grown by 1,958.3%.
- Historical annual values: Fiscal year 2025: $53.41 million | Fiscal year 2024: $120.75 million | Fiscal year 2023: $125.70 million | Fiscal year 2022: $160.82 million | Fiscal year 2021: $261.31 million | Fiscal year 2020: -$15.65 million | Fiscal year 2019: -$2.87 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: